{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T23:04:25Z","timestamp":1765926265627,"version":"3.48.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc. Diabetol. \u2013 Endocrinol. Rep."],"DOI":"10.1186\/s40842-025-00253-5","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T23:02:25Z","timestamp":1765926145000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum PCSK9 is not independently associated with dyslipidaemia in type 2 diabetes: a paired cross-sectional study"],"prefix":"10.1186","volume":"11","author":[{"given":"Peace Ngozi","family":"Okoro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kolawole Wasiu","family":"Wahab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Kola","family":"Olarinoye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biliaminu Sikiru","family":"Abayomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"issue":"5","key":"253_CR1","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","volume":"27","author":"S Wild","year":"2004","unstructured":"Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047\u201353.","journal-title":"Diabetes Care"},{"issue":"10","key":"253_CR2","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1161\/01.CIR.100.10.1134","volume":"100","author":"SM Grundy","year":"1999","unstructured":"Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Sowers JR. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American heart association. Circulation. 1999;100(10):1134\u201346.","journal-title":"Circulation"},{"issue":"3","key":"253_CR3","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1210\/jcem.86.3.7304","volume":"86","author":"IJ Goldberg","year":"2001","unstructured":"Goldberg IJ. Diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metabolism. 2001;86(3):965\u201371.","journal-title":"J Clin Endocrinol Metabolism"},{"key":"253_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s42000-018-0014-8","volume":"17","author":"VG Athyros","year":"2018","unstructured":"Athyros VG, Doumas M, Imprialos KP, Stavropoulos K, Georgianou E, Katsimardou A, Karagiannis A. Diabetes and lipid metabolism. Hormones. 2018;17:61\u20137.","journal-title":"Hormones"},{"issue":"2","key":"253_CR5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel M, Varret M, Rab\u00e8s JP, Allard D, Ouguerram K, Devillers M, Boileau C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154\u20136.","journal-title":"Nat Genet"},{"issue":"12","key":"253_CR6","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1042\/CS20140832","volume":"128","author":"M Guardiola","year":"2015","unstructured":"Guardiola M, Plana N, Ibarretxe D, Cabr\u00e9 A, Gonz\u00e1lez M, Ribalta J, Masana L. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk. Clin Sci (Lond). 2015;128(12):877\u201382.","journal-title":"Clin Sci (Lond)"},{"issue":"4","key":"253_CR7","doi-asserted-by":"publisher","first-page":"574","DOI":"10.5603\/CJ.a2021.0110","volume":"29","author":"Q Geng","year":"2022","unstructured":"Geng Q, Li X, Sun Q, Wang Z. Efficacy and safety of PCSK9 Inhibition in cardiovascular disease: a meta-analysis of 45 randomized controlled trials. Cardiol J. 2022;29(4):574\u201381.","journal-title":"Cardiol J"},{"issue":"6","key":"253_CR8","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.drudis.2017.01.006","volume":"22","author":"AA Momtazi","year":"2017","unstructured":"Momtazi AA, Banach M, Pirro M, Stein EA, Sahebkar A. PCSK9 and diabetes: is there a link? Drug Discovery Today. 2017;22(6):883\u201395.","journal-title":"Drug Discovery Today"},{"key":"253_CR9","doi-asserted-by":"crossref","unstructured":"Mba CM, Mbacham W, Sobngwi E, Mbanya JC. Is PCSK9 associated with plasma lipid levels in a sub-Saharan African population of patients with obesity and type 2 diabetes? Diabetes Metabolic Syndrome Obesity: Targets Therapy. 2019;2791\u20137.","DOI":"10.2147\/DMSO.S234243"},{"issue":"9","key":"253_CR10","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/gerona\/glu035","volume":"69","author":"DO Clark","year":"2014","unstructured":"Clark DO, Gao S, Lane KA, Callahan CM, Baiyewu O, Ogunniyi A, Hendrie HC. Obesity and 10-year mortality in very old African Americans and Yoruba-Nigerians: exploring the obesity paradox. Journals Gerontol Ser A: Biomedical Sci Med Sci. 2014;69(9):1162\u20139.","journal-title":"Journals Gerontol Ser A: Biomedical Sci Med Sci"},{"issue":"1","key":"253_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1469-1809.1940.tb02236.x","volume":"10","author":"H Jeffreys","year":"1940","unstructured":"Jeffreys H. Note on the Behrens-Fisher formula. Annals Eugenics. 1940;10(1):48\u201351.","journal-title":"Annals Eugenics"},{"key":"253_CR12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jchromb.2016.12.040","volume":"1044","author":"M Croyal","year":"2017","unstructured":"Croyal M, Fall F, Krempf M, Th\u00e9drez A, Ouguerram K, Ferchaud-Roucher V, Nob\u00e9court E. Plasma PCSK9 measurement by liquid chromatography\u2013Tandem mass spectrometry and comparison with conventional ELISA. J Chromatogr B. 2017;1044:24\u20139.","journal-title":"J Chromatogr B"},{"key":"253_CR13","doi-asserted-by":"crossref","unstructured":"Armstrong D, Browne R. (1994). The analysis of free radicals, lipid peroxides, antioxidant enzymes and compounds related to oxidative stress as applied to the clinical chemistry laboratory. Free radicals in diagnostic medicine: a systems approach to laboratory technology, clinical correlations, and antioxidant therapy, 43\u201358.","DOI":"10.1007\/978-1-4615-1833-4_4"},{"issue":"5","key":"253_CR14","first-page":"266","volume":"4","author":"RP Agrawal","year":"2013","unstructured":"Agrawal RP, Sharma N, Rathore MS, Gupta VB, Jain S, Agarwal V, Goyal S. Noninvasive method for glucose level Estimation by saliva. J Diabetes Metab. 2013;4(5):266.","journal-title":"J Diabetes Metab"},{"key":"253_CR15","doi-asserted-by":"crossref","unstructured":"Prathima MB, Reshma S, Shetty P, Janice DS, Kalal BS. & MADAN, G. R. (2020). Estimation of glycated haemoglobin by Nephelometry, ion exchange resin and high performance liquid chromatography: A Cross-sectional study. J Clin Diagn Res, 14(9).","DOI":"10.7860\/JCDR\/2020\/44408.13968"},{"issue":"3","key":"253_CR16","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1210\/endrev\/bnab035","volume":"43","author":"NG Seidah","year":"2022","unstructured":"Seidah NG, Prat A. The multifaceted biology of PCSK9. Endocr Rev. 2022;43(3):558\u201382.","journal-title":"Endocr Rev"},{"issue":"18","key":"253_CR17","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Pedersen TR. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"22","key":"253_CR18","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Zeiher AM. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"issue":"1","key":"253_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1476-511X-7-22","volume":"7","author":"J Mayne","year":"2008","unstructured":"Mayne J, Dewpura T, Raymond A, Cousins M, Chaplin A, Lahey KA, Chr\u00e9tien M. Plasma PCSK9 levels are significantly modified by Statins and fibrates in humans. Lipids Health Dis. 2008;7(1):22.","journal-title":"Lipids Health Dis"},{"issue":"6","key":"253_CR20","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1194\/jlr.M003566","volume":"51","author":"B Dong","year":"2010","unstructured":"Dong B, Wu M, Li H, Kraemer FB, Adeli K, Seidah NG, Liu J. Strong induction of PCSK9 gene expression through HNF1\u03b1 and SREBP2: mechanism for the resistance to LDL-cholesterol Lowering effect of Statins in dyslipidemic hamsters. J Lipid Res. 2010;51(6):1486\u201395.","journal-title":"J Lipid Res"},{"issue":"12","key":"253_CR21","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1161\/ATVBAHA.110.214130","volume":"30","author":"L Persson","year":"2010","unstructured":"Persson L, Cao G, Stahle L, Sjoberg BG, Troutt JS, Konrad RJ, Rudling M. Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. Arterioscler Thromb Vasc Biol. 2010;30(12):2666\u201372.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"253_CR22","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/MOL.0000000000000114","volume":"25","author":"TA Lagace","year":"2014","unstructured":"Lagace TA. PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. Curr Opin Lipidol. 2014;25(5):387\u201393.","journal-title":"Curr Opin Lipidol"},{"issue":"9","key":"253_CR23","doi-asserted-by":"publisher","first-page":"895","DOI":"10.5551\/jat.RV17012","volume":"24","author":"T Nozue","year":"2017","unstructured":"Nozue T. Lipid Lowering therapy and Circulating PCSK9 concentration. J Atheroscler Thromb. 2017;24(9):895\u2013907.","journal-title":"J Atheroscler Thromb"},{"issue":"6","key":"253_CR24","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00125-003-1111-y","volume":"46","author":"MR Taskinen","year":"2003","unstructured":"Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003;46(6):733\u201349.","journal-title":"Diabetologia"},{"issue":"5","key":"253_CR25","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1007\/s00125-015-3525-8","volume":"58","author":"B Verg\u00e8s","year":"2015","unstructured":"Verg\u00e8s B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia. 2015;58(5):886\u201399.","journal-title":"Diabetologia"},{"key":"253_CR26","doi-asserted-by":"crossref","unstructured":"ElSayed NA, Aleppo G, Bannuru RR, Bruemmer D, Collins BS, Das SR, et al.; American Diabetes Association Professional Practice Committee. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes\u20142024. Diabetes Care. 2024;47.","DOI":"10.2337\/dc24-S010"},{"issue":"4","key":"253_CR27","doi-asserted-by":"publisher","first-page":"304","DOI":"10.21037\/cdt.2015.10.03","volume":"6","author":"K Takata","year":"2016","unstructured":"Takata K, Imaizumi S, Zhang B, Miura SI, Saku K. Stabilization of high-risk plaques. Cardiovasc Diagnosis Therapy. 2016;6(4):304.","journal-title":"Cardiovasc Diagnosis Therapy"},{"issue":"5","key":"253_CR28","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.pcad.2019.11.005","volume":"62","author":"NJ Stone","year":"2019","unstructured":"Stone NJ, Grundy SM. The 2018 AHA\/ACC\/Multi-Society cholesterol guidelines: looking at past, present and future. Prog Cardiovasc Dis. 2019;62(5):375\u201383.","journal-title":"Prog Cardiovasc Dis"},{"key":"253_CR29","doi-asserted-by":"crossref","unstructured":"Pan X, Mota S, Zhang B. (2020). Circadian clock regulation on lipid metabolism and metabolic diseases. Lipid Transf Lipoprotein Metabolism Cardiovasc Disease, 53\u201366.","DOI":"10.1007\/978-981-15-6082-8_5"},{"issue":"3","key":"253_CR30","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1586\/erc.11.182","volume":"10","author":"D Farbstein","year":"2012","unstructured":"Farbstein D, Levy AP. HDL dysfunction in diabetes: causes and possible treatments. Expert Rev Cardiovasc Ther. 2012;10(3):353\u201361.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"2","key":"253_CR31","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/MED.0000000000000705","volume":"29","author":"MJ Chapman","year":"2022","unstructured":"Chapman MJ. HDL functionality in type 1 and type 2 diabetes: new insights. Curr Opin Endocrinol Diabetes Obes. 2022;29(2):112\u201323.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"1","key":"253_CR32","first-page":"167","volume":"440","author":"RAK Srivastava","year":"2018","unstructured":"Srivastava RAK. Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease. Mol Cell Biochem. 2018;440(1):167\u201387.","journal-title":"Mol Cell Biochem"},{"key":"253_CR33","doi-asserted-by":"crossref","unstructured":"Vaisar T, Couzens E, Hwang A, Russell M, Barlow CE, DeFina LF, et al. Type 2 diabetes is associated with loss of HDL endothelium protective functions. PLoS One. 2018;13(3):e0192616.","DOI":"10.1371\/journal.pone.0192616"},{"issue":"Suppl 2","key":"253_CR34","doi-asserted-by":"publisher","first-page":"S384","DOI":"10.2337\/dc09-S345","volume":"32","author":"R Eldor","year":"2009","unstructured":"Eldor R, Raz I. American diabetes association indications for Statins in diabetes: is there evidence? Diabetes Care. 2009;32(Suppl 2):S384.","journal-title":"Diabetes Care"},{"key":"253_CR35","doi-asserted-by":"crossref","unstructured":"Karimi MA, Vaezi A, Ansari A, Archin I, Dadgar K, Rasouli A, et al. Lipid variability and risk of microvascular complications in patients with diabetes: a systematic review and meta-analysis. BMC Endocr Disord. 2024;24(1):4.","DOI":"10.1186\/s12902-023-01526-9"},{"issue":"12","key":"253_CR36","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s11883-022-01074-y","volume":"24","author":"S Carugo","year":"2022","unstructured":"Carugo S, Sirtori CR, Corsini A, Tokgozoglu L, Ruscica M. PCSK9 Inhibition and risk of diabetes: should we worry? Curr Atheroscler Rep. 2022;24(12):995\u20131004.","journal-title":"Curr Atheroscler Rep"},{"key":"253_CR37","doi-asserted-by":"crossref","unstructured":"Wiviott SD, Giugliano RP, Morrow DA, De Ferrari GM, Lewis BS, Huber K, et al. Effect of evolocumab on type and size of subsequent myocardial infarction: a prespecified analysis of the FOURIER randomized clinical trial. JAMA Cardiol. 2020;5(7):787-93.","DOI":"10.1001\/jamacardio.2020.0764"},{"key":"253_CR38","doi-asserted-by":"crossref","unstructured":"Schwartz GG, Steg PG, Bhatt DL, Bittner VA, Diaz R, Goodman SG, et al.; ODYSSEY OUTCOMES Committees and Investigators. Clinical efficacy and safety of alirocumab after acute coronary syndrome according to achieved level of low-density lipoprotein cholesterol: a propensity score\u2013matched analysis of the ODYSSEY OUTCOMES trial. Circulation. 2021;143(11):1109-22.","DOI":"10.1161\/CIRCULATIONAHA.120.049447"},{"issue":"3","key":"253_CR39","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s11239-016-1364-1","volume":"42","author":"J Latimer","year":"2016","unstructured":"Latimer J, Batty JA, Neely RDG, Kunadian V. PCSK9 inhibitors in the prevention of cardiovascular disease. J Thromb Thrombolysis. 2016;42(3):405\u201319.","journal-title":"J Thromb Thrombolysis"}],"container-title":["Cardiovascular Diabetology \u2013 Endocrinology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-025-00253-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40842-025-00253-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-025-00253-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T23:02:30Z","timestamp":1765926150000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40842-025-00253-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["253"],"URL":"https:\/\/doi.org\/10.1186\/s40842-025-00253-5","relation":{},"ISSN":["3059-4057"],"issn-type":[{"value":"3059-4057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study\u2019s protocol obtained ethical approval from the Research and Ethics Committee of the University of Ilorin Teaching Hospital, Ilorin, identified by Protocol ID No: UITH\/CAT\/189\/21\n                      8\n                      \/190. Approval date was 06\/07\/2021. Informed consent was taken from all subjects involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}